Leeds-based Deepmatter has revealed a new look, both for its Board and its branding.
The company, now called ChemAI, stated that the rebrand was part of a strategic growth plan to “revolutionise the future of chemistry with artificial intelligence.”
“The rebrand to ChemAI reflects our bold ambition to redefine the role of data and AI in chemistry,” said Chairman, Dave Norwood.
“By combining a visionary approach with a strengthened leadership team, ChemAI is well-positioned to drive transformative change and unlock unprecedented opportunities in the chemical and pharmaceutical industries.”
Norwood is also one of the main changes to its Board, having been appointed Chairman. The founder of IP Group PLC and Oxford Science Enterprises, which has driven over £1.5 billion in investments into Oxford since 2015. He also co-founded Oxford Nanopore, a global leader in DNA sequencing.
Joining him is Tony de Fougerolles, who becomes a Non-Executive Director, bringing over 25 years of experience in biotechnology R&D, most recently as CEO of Evox Therapeutics.
“I’m thrilled to join ChemAI at such an exciting juncture,” he said.
“The company’s AI-powered platform has immense potential to accelerate innovation and improve efficiencies across the chemical ecosystem. Our approach to AI won’t replace chemists entirely, but chemists using our tools will be immeasurably more productive and creative than those that don’t”
ChemAI has offices in Leeds, Glasgow, Munich and Lyon, developing and commercialising AI driven tools for chemists. Its AI is underpinned by access to proprietary data: a “comprehensive and growing” chemical database of over 23m chemical reactions.
